复宏汉霖(02696)：注射用HLX43联合HLX07或汉斯状®在晚期或转移性结直肠癌患者中开展的1b/2期临床研究于中国境内完成首例患者给药

Core Viewpoint - The announcement from Junshi Biosciences (复宏汉霖) indicates the initiation of a clinical study for HLX43 in combination with HLX07 or Hansizhuang (汉斯状®) for patients with advanced or metastatic colorectal cancer in mainland China [1] Group 1 - Junshi Biosciences has completed the first patient dosing in a 1b/2 phase clinical study for HLX43, a PD-L1 targeted antibody-drug conjugate [1] - The study involves the combination of HLX43 with HLX07, a recombinant humanized monoclonal antibody injection targeting EGFR, or Hansizhuang, a monoclonal antibody injection [1] - The clinical research is being conducted in mainland China, excluding Hong Kong, Macau, and Taiwan [1]